左心室功能、淤血与恩格列净对心肌梗死后心力衰竭风险的影响
基于EMPACT-MI试验,在急性心肌梗死后14天内随机给予恩格列净10mg每日一次或安慰剂,中位随访17.9个月。结果显示左室射血分数降低和淤血均与不良结局风险升高相关,恩格列净可降低首次和总心力衰竭住院风险,且不受左室射血分数或淤血状态影响。
要点
- 急性心梗后左室射血分数每降低10点,全因死亡或心衰住院风险增加49%。
- 淤血的存在与全因死亡或心衰住院风险增加52%相关。
核心结论
- 急性心肌梗死后左室功能障碍严重程度和淤血存在与更差结局相关。
- 恩格列净在左室射血分数范围和有无淤血情况下均降低首次和总心力衰竭住院风险。
研究设计与样本
- EMPACT-MI试验为随机对照试验,在急性心肌梗死后14天内将患者随机分配至恩格列净10mg每日一次或安慰剂。
- 共纳入6522例患者,中位随访17.9个月。
主要发现
- 基线平均左室射血分数为41±9%;2648例(40.6%)仅左室射血分数<45%,1483例(22.7%)仅淤血,2181例(33.4%)两者均有。
- 安慰剂组中,左室射血分数每降低10点,全因死亡或心衰住院风险比1.49(95%CI 1.31-1.69,P<0.0001),首次心衰住院风险比1.64(95%CI 1.37-1.96,P<0.0001),总心衰住院率比1.89(95%CI 1.51-2.36,P<0.0001)。
- 淤血存在与全因死亡或心衰住院风险比1.52、首次心衰住院风险比1.94、总心衰住院率比2.03相关。
- 恩格列净降低首次心衰住院风险比0.77(95%CI 0.60-0.98)和总心衰住院率比0.67(95%CI 0.50-0.89),不受左室射血分数或淤血状态影响。
- 恩格列净安全性在基线左室射血分数范围和淤血状态间一致。
临床怎么用
- 急性心肌梗死后无论左室射血分数高低或有无淤血,均可考虑使用恩格列净以降低心力衰竭住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). OBJECTIVES: This study sought to evaluate the association of left ventricular ejection fraction (LVEF), congestion, or both, with outcomes and the impact of empagliflozin in reducing HF risk post-AMI. METHODS: In the EMPACT-MI (Trial to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction) trial, patients were randomized within 14 days of an AMI complicated by either newly reduced LVEF<45%, congestion, or both, to empagliflozin (10 mg daily) or placebo and were followed up for a median of 17.9 months. RESULTS: Among 6,522 patients, the mean baseline LVEF was 41 ± 9%; 2,648 patients (40.6%) presented with LVEF <45% alone, 1,483 (22.7%) presented with congestion alone, and 2,181 (33.4%) presented with both. Among patients in the placebo arm of the trial, multivariable adjusted risk for each 10-point reduction in LVEF included all-cause death or HF hospitalization (HR: 1.49; 95% CI: 1.31-1.69; P < 0.0001), first HF hospitalization (HR: 1.64; 95% CI: 1.37-1.96; P < 0.0001), and total HF hospitalizations (rate ratio [RR]: 1.89; 95% CI: 1.51-2.36; P < 0.0001). The presence of congestion was also associated with a significantly higher risk for each of these outcomes (HR: 1.52, 1.94, and RR: 2.03, respectively). Empagliflozin reduced the risk for first (HR: 0.77; 95% CI: 0.60-0.98) and total (RR: 0.67; 95% CI: 0.50-0.89) HF hospitalizations, irrespective of LVEF or congestion, or both. The safety profile of empagliflozin was consistent across baseline LVEF and irrespective of congestion status. CONCLUSIONS: In patients with AMI, the severity of left ventricular dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion. (Trial to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction [EMPACT-MI]; NCT04509674).
引用
- Udell, Petrie, Jones, et al. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction. J Am Coll Cardiol. 2024. PMID: 38588929. doi:10.1016/j.jacc.2024.03.405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。